Abstract
The occurrence of metabolic syndrome (MS) represents an independent risk factor for developing cardiovascular disease states in patients suffering from type 2 diabetes mellitus. Moreover, both the size of LDL particles and liver dysfunction identified as non alcoholic steato-hepatitis (NASH) represent important biomarkers for the development of cardiometabolic risk in patients with MS. Recent evidence shows that bergamot polyphenolic fraction (BPF) in patients with MS and NASH induces a significant reduction of fasting plasma glucose, serum LDL cholesterol and triglycerides alongside with an increase of HDL cholesterol. In addition, a significant reduction of both ultrasonographic, TC scans and metabolic biomarkers of NASH as well as a significant reduction of small dense LDL particles were found after BPF treatment suggesting a beneficial effect of bergamot-extract in patients with MS and NASH. This suggests a potential preventive role of bergamot derivatives in reducing cardiometabolic risk.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
